Tandem Diabetes Care to Announce Third Quarter 2024 Financial Results on November 6, 2024

TNDM 10.02.2024

Full Press ReleaseSEC FilingsOur TNDM Tweets

About Gravity Analytica

Recent News

  • 02.26.2025 - Tandem Diabetes Care Q4 2024 Earnings
  • 01.15.2025 - Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
  • 01.07.2025 - Tandem Diabetes Care Enters Multi-Year Research Collaboration with UVA Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems

Recent Filings

  • 12.18.2024 - 4 Statement of changes in beneficial ownership of securities
  • 11.21.2024 - 144 Report of proposed sale of securities
PDF Version

SAN DIEGO--(BUSINESS WIRE)--Oct. 2, 2024--Tandem Diabetes Care, Inc.(NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2024 results after the financial markets close onWednesday, November 6, 2024. The Company will hold a conference call and simultaneous webcast on the same day at4:30 pm Eastern Time(1:30 pm Pacific Time), to discuss its third quarter 2024 financial and operating results.

A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located athttp://investor.tandemdiabetes.comin the “Events & Presentations” section. To access the call by phone, please use this link (https://register.vevent.com/register/BI21747dfdc3fd4a4e98aeeeef73bf87b6) and you will be provided with dial-in details, including a personal pin.

An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located athttp://investor.tandemdiabetes.comin the “Events & Presentations” section.

AboutTandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology.Tandem Diabetes Careis based inSan Diego, California. For more information, visittandemdiabetes.com.

Tandem Diabetes Care, the Tandem logo, Control-IQ, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks ofTandem Diabetes Care, Inc.inthe United Statesand/or other countries.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241002126716/en/

Media Contact:858-366-6900media@tandemdiabetes.com

Investor Contact:858-366-6900IR@tandemdiabetes.com

Source:Tandem Diabetes Care, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com